Interestingly, CX-4945 treatment lowered HMGB1, β-catenin, C-MYC, phosphor-MAX, IL-6, and CSNK2A1 protein levels in tumor tissues in CX-4945 treatment as compared with a vehicle (Figure 8K). The gene discussed is CSNK2A1; the disease is neoplasm.